Li Chun Han
Director/Board Member bei MICROBIO CO., LTD.
Profil
Li Chun Han is an Independent Director at StemCyte, Inc., Microbio Co., Ltd., Stemcyte Taiwan, and Sinew Pharma, Inc. He previously served as Chairman at President Futures Corp.
and Deputy General Manager at President Securities Corp.
He obtained an undergraduate degree from National Chung Hsing University.
Aktive Positionen von Li Chun Han
Unternehmen | Position | Beginn |
---|---|---|
MICROBIO CO., LTD. | Director/Board Member | 06.06.2012 |
SINEW PHARMA INC. | Director/Board Member | 27.06.2019 |
StemCyte, Inc.
StemCyte, Inc. BiotechnologyHealth Technology StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA. | Director/Board Member | 24.04.2014 |
Stemcyte Taiwan
Stemcyte Taiwan Medical/Nursing ServicesHealth Services Stemcyte Taiwan, founded in 2000, is a private company based in New Taipei City, Taiwan that specializes in umbilical cord blood banking. Stemcyte Taiwan has been recognized by over 350 medical centers worldwide and has helped with over 2,500 cord blood transplants. The Taiwanese company has a large public cord blood bank and exclusive patent technology for red blood cell separation. Stemcyte Taiwan has received international accreditations from AABB, FACT, NMDP, WMDA, and FDA, providing customers with secure and transparent contracts. | Director/Board Member | - |
Ehemalige bekannte Positionen von Li Chun Han
Unternehmen | Position | Ende |
---|---|---|
President Futures Corp.
President Futures Corp. Investment Banks/BrokersFinance Part of Uni-President Enterprises Corp., President Futures Corp. is a financial company based in Taipei, Taiwan. The Taiwanese company specializes in providing investors with a tool to hedge against interest rate risks and to capitalize on potential profits from interest rate changes through the use of financial derivatives, specifically the US Treasury bond futures. The private company offers a comprehensive guide on the basic concepts, operational principles, and factors affecting the price of US Treasury bond futures. The guide also includes information on the types of US Treasury bonds, the contract specifications of US Treasury bond futures, and how to calculate profits and losses. The company's services are mainly targeted towards institutional investors who hold large amounts of bonds and require flexible trading options. | Chairman | - |
PRESIDENT SECURITIES CORPORATION | Corporate Officer/Principal | - |
Ausbildung von Li Chun Han
National Chung Hsing University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
PRESIDENT SECURITIES CORPORATION | Finance |
MICROBIO CO., LTD. | Health Technology |
SINEW PHARMA INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
StemCyte, Inc.
StemCyte, Inc. BiotechnologyHealth Technology StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA. | Health Technology |
President Futures Corp.
President Futures Corp. Investment Banks/BrokersFinance Part of Uni-President Enterprises Corp., President Futures Corp. is a financial company based in Taipei, Taiwan. The Taiwanese company specializes in providing investors with a tool to hedge against interest rate risks and to capitalize on potential profits from interest rate changes through the use of financial derivatives, specifically the US Treasury bond futures. The private company offers a comprehensive guide on the basic concepts, operational principles, and factors affecting the price of US Treasury bond futures. The guide also includes information on the types of US Treasury bonds, the contract specifications of US Treasury bond futures, and how to calculate profits and losses. The company's services are mainly targeted towards institutional investors who hold large amounts of bonds and require flexible trading options. | Finance |
Stemcyte Taiwan
Stemcyte Taiwan Medical/Nursing ServicesHealth Services Stemcyte Taiwan, founded in 2000, is a private company based in New Taipei City, Taiwan that specializes in umbilical cord blood banking. Stemcyte Taiwan has been recognized by over 350 medical centers worldwide and has helped with over 2,500 cord blood transplants. The Taiwanese company has a large public cord blood bank and exclusive patent technology for red blood cell separation. Stemcyte Taiwan has received international accreditations from AABB, FACT, NMDP, WMDA, and FDA, providing customers with secure and transparent contracts. | Health Services |